Trade-offs between drug toxicity and benefit in the multi-antibiotic resistance system underlie optimal growth of E. coli

BackgroundEfflux is a widespread mechanism of reversible drug resistance in bacteria that can be triggered by environmental stressors, including many classes of drugs. While such chemicals when used alone are typically toxic to the cell, they can also induce the efflux of a broad range of agents and may therefore prove beneficial to cells in the presence of multiple stressors. The cellular response to a combination of such chemical stressors may be governed by a trade-off between the fitness costs due to drug toxicity and benefits mediated by inducible systems. Unfortunately, disentangling the cost-benefit interplay using measurements of bacterial growth in response to the competing effects of the drugs is not possible without the support of a theoretical framework.ResultsHere, we use the well-studied multiple antibiotic resistance (MAR) system in E. coli to experimentally characterize the trade-off between drug toxicity (“cost”) and drug-induced resistance (“benefit”) mediated by efflux pumps. Specifically, we show that the combined effects of a MAR-inducing drug and an antibiotic are governed by a superposition of cost and benefit functions that govern these trade-offs. We find that this superposition holds for all drug concentrations, and it therefore allows us to describe the full dose–response diagram for a drug pair using simpler cost and benefit functions. Moreover, this framework predicts the existence of optimal growth at a non-trivial concentration of inducer. We demonstrate that optimal growth does not coincide with maximum induction of the mar promoter, but instead results from the interplay between drug toxicity and mar induction. Finally, we derived and experimentally validated a general phase diagram highlighting the role of these opposing effects in shaping the interaction between two drugs.ConclusionsOur analysis provides a quantitative description of the MAR system and highlights the trade-off between inducible resistance and the toxicity of the inducing agent in a multi-component environment. The results provide a predictive framework for the combined effects of drug toxicity and induction of the MAR system that are usually masked by bulk measurements of bacterial growth. The framework may also be useful for identifying optimal growth conditions in more general systems where combinations of environmental cues contribute to both transient resistance and toxicity.

[1]  R. Kishony,et al.  Antibiotic interactions that select against resistance , 2007, Nature.

[2]  J. Rosner Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in Escherichia coli K-12. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Fralick Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli , 1996, Journal of bacteriology.

[4]  S. Levy,et al.  Active efflux, a common mechanism for biocide and antibiotic resistance , 2002, Journal of applied microbiology.

[5]  S. Levy,et al.  Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathway , 1993, Journal of bacteriology.

[6]  G. Sethi,et al.  Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. , 2010, Biochimica et biophysica acta.

[7]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[8]  P. Pomposiello,et al.  The mar Regulon , 2005 .

[9]  H. Mori,et al.  Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection , 2006, Molecular systems biology.

[10]  H. Nikaido,et al.  AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants , 1996, Journal of bacteriology.

[11]  S. Levy,et al.  Active efflux mechanisms for antimicrobial resistance , 1992, Antimicrobial Agents and Chemotherapy.

[12]  Remy Chait,et al.  Correction: Optimal Drug Synergy in Antimicrobial Treatments , 2010, PLoS Computational Biology.

[13]  S. Levy,et al.  Identification for mar mutants among quinolone-resistant clinical isolates of Escherichia coli , 1996, Antimicrobial agents and chemotherapy.

[14]  R. Kishony,et al.  Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.

[15]  S. Levy,et al.  Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon , 1997, Antimicrobial agents and chemotherapy.

[16]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[17]  Michael E. Wall,et al.  Model of Transcriptional Activation by MarA in Escherichia coli , 2009, PLoS Comput. Biol..

[18]  Remy Chait,et al.  Optimal Drug Synergy in Antimicrobial Treatments , 2010, PLoS Comput. Biol..

[19]  D. Hooper,et al.  Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction , 1989, Antimicrobial Agents and Chemotherapy.

[20]  J. Molnár,et al.  Inducement and Reversal of Tetracycline Resistance in Escherichia coli K-12 and Expression of Proton Gradient-Dependent Multidrug Efflux Pump Genes , 2005, Antimicrobial Agents and Chemotherapy.

[21]  A. M. George,et al.  Active efflux of chloramphenicol in susceptible Escherichia coli strains and in multiple-antibiotic-resistant (Mar) mutants , 1994, Antimicrobial Agents and Chemotherapy.

[22]  C. I. Bliss THE CALCULATION OF MICROBIAL ASSAYS , 1956 .

[23]  J. Gustafson,et al.  The effects of salicylate on bacteria. , 2000, The international journal of biochemistry & cell biology.

[24]  A. M. George,et al.  Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline , 1983, Journal of bacteriology.

[25]  S. Loewe The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[26]  D. A. Golden,et al.  Transcription analysis of stx1, marA, and eaeA genes in Escherichia coli O157:H7 treated with sodium benzoate. , 2008, Journal of food protection.

[28]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[29]  D. Hartl,et al.  Accelerated evolution of resistance in multidrug environments , 2008, Proceedings of the National Academy of Sciences.

[30]  P. Venkatesan,et al.  Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.

[31]  S. Levy,et al.  The mar regulon: multiple resistance to antibiotics and other toxic chemicals. , 1999, Trends in microbiology.

[32]  H. Bujard,et al.  Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. , 1997, Nucleic acids research.

[33]  R. Kishony,et al.  A Differential Drug Screen for Compounds That Select Against Antibiotic Resistance , 2010, PloS one.

[34]  Remy Chait,et al.  Drug interactions modulate the potential for evolution of resistance , 2008, Proceedings of the National Academy of Sciences.

[35]  P. Cluzel,et al.  Dynamical determinants of drug-inducible gene expression in a single bacterium. , 2006, Biophysical journal.

[36]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[37]  J. Vila,et al.  Enhanced active efflux, repression of porin synthesis and development of Mar phenotype by diazepam in two enterobacteria strains. , 2004, Journal of medical microbiology.

[38]  S. Levy,et al.  marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli , 1988, Journal of bacteriology.

[39]  D. Hooper,et al.  Endogenous active efflux of norfloxacin in susceptible Escherichia coli , 1988, Antimicrobial Agents and Chemotherapy.

[40]  B. Seaton,et al.  The crystal structure of MarR, a regulator of multiple antibiotic resistance, at 2.3 Å resolution , 2001, Nature Structural Biology.